0 of 21 questions completed
Questions:
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 21 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
In order to have a diagnosis of AML, patients must:
The pharmacist plays a crucial role in supporting the treatment of AML patients by:
Risk factors for AML include:
Anthracyclines are an important part of the backbone of 7 + 3 therapy for AML. What common toxicities are seen with their use?
In a clinical trial for high risk AML patients who were 60 – 75 years old, the addition of Vyxeos™ (daunorubicin and cytarabine) to the standard 7 + 3 treatment, resulted in:
In the clinical trial, RATIFY, the agent midostaurin was added to the standard 7 + 3 regimen for a randomized group of patients, 18 – 60 years of age. The control group was given the 7 + 3 regimen and a placebo. The patients who were given midostaurin:
Elderly AML patients who are unfit:
What are complications that AML patients may go through following stem cell transplant:
Following induction but before stem cell transplant, what are some important options that couples have in managing fertility:
How is treatment for an AML patient who relapses 2 years (long-term) after remission different from treatment for a patient who relapses 6 months (short-term) after remission:
Cytogenetic normal acute myeloid leukemia (AML) is:
Which of the following are used to diagnosis AML?
Goals of treatment in AML include inducing remission with a focus on improving quality of life for which of the following groups?
Consolidation therapy in favorable risk AML is most likely to include:
The most common toxicity in patients receiving ATRA (al trans retinoic acid) and arsenic trioxide is:
Why do younger AML patients have a higher rate of survival than older patients?
Why is the advent of risk (molecular) stratification in AML based on cytogenetics or karytype analysis, such an important scientific breakthrough?
Which is not a significant characteristic of Acute Promyelocytic leukemia (APL)?
Which statement (below) is true regarding the targeted treatment of APL with ATRA:
The most commonly reported symptom associated with anemia is:
The nurse’s role in treating the side effects of neutropenia includes: